Loading clinical trials...
Loading clinical trials...
A Phase 2 Study of Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma
Conditions
Interventions
Pegylated Interferon alpha-2b
Capecitabine
+1 more
Locations
1
United States
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
Start Date
August 12, 2014
Primary Completion Date
July 19, 2017
Completion Date
June 25, 2018
Last Updated
October 7, 2022
NCT04099290
NCT06912087
NCT04429542
NCT04564989
NCT05955924
NCT03485209
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions